Baxalta — Q1 2016 Earnings Presentation
36 slides from Baxalta's earnings presentation, Apr 28, 2016
Slide 1: First Quarter 2016 Financial Results And Business Performance Update
Exhibit 99.2 Baxalta Incorporated First Quarter 2016 Financial Results And Business Performance Update April 28 th , 2016
Slide 2: Forward-Looking Statements And GAAP Reconciliation
Forward-Looking Statements And GAAP Reconciliation “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation includes forward- looking statements concerning expectations and other matters that are dependent upon future events or developments. Such statemen
Slide 3: Table Of Contents
Table Of Contents
Slide 4: Strong Execution Validates Baxalta's Commitment To Enhancing Shareholder Value
Strong Execution Validates Baxalta’s Commitment To Enhancing Shareholder Value Sustaining growth and value across the portfolio • Generating positive sales momentum across broad and diversified portfolio • Demonstrating compelling commercial, regulatory, operational & financial execution Achieving ~
Slide 5: Driving Sustainable Growth And Value
Driving Sustainable Growth And Value Leadership Capabilities Value $6 billion global 100+ countries of ~20 new product biopharmaceutical operation launches expected by 2020 leader Q1 2016 Sales By Product Category* Q1 2016 Sales By Geography* $ In Millions $ In Millions *Growth compares to 2015 pro
Slide 6: Driving Strong Q1 2016 Financial Results
Driving Strong Q1 2016 Financial Results Sales Growth* Adjusted EPS** % Sales Growth At Constant Currency $ Per Diluted Share Continued Momentum Across Portfolio Drives Strong Sales And Earnings Growth *Growth rates are at constant currency and compare to 2015 pro forma sales **Financial results and
Slide 7: Our Pipeline Is Delivering Results
Our Pipeline Is Delivering Results Key Regulatory Approvals ONIVYDE 20% IGSC New Products In EU U.S. & EU Regulatory Review New Product Revenue New Product ~$300 Million ~$750 Million Launches By 2020 2015 Actual Results 2016 Expectation Baxalta Performance Update | Q1 2016 | Page 7
Slide 8: Unlocking Value With New Product Revenues
Unlocking Value With New Product Revenues Quarterly New Product Sales Trend* 2016 New Product Sales Expectation = ~$750 Million *New product sales exclude impact of inventory stocking Baxalta Performance Update | Q1 2016 | Page 8
Slide 9: Achieving Key Milestones In Q1 2016
Achieving Key Milestones In Q1 2016 Received Japan approval; submitted applications for regulatory approval in EU and ADYNOVATE for pediatric & surgical indications in U.S. OBIZUR Launched in EU BAX 826 Initiated Phase I trial targeting once-weekly dosing regimen for hemophilia A HYQVIA (PID) Receiv
Slide 10: 2016 Pipeline Catalysts
2016 Pipeline Catalysts Clinical Regulatory Product Advancements Filings Approvals ONIVYDE Calaspargase Pegol (Phase III Data) Pancreatic 2 nd Line (EU) Alpha-1 ONIVYDE BAX 2200 st ONCASPAR GvHD Pancreatic 1 Line Etanercept (EU) (Initiate Phase III) (Initiate Phase III) (EU) HYQVIA BAX 923 MyPKFiT H
Slide 11: Building A Robust And Diverse Pipeline: Key Programs
Building A Robust And Diverse Pipeline: Key Programs* Program Pre-Clinical Phase I Phase II Phase III Reg. Review Approved EHL rFVIII PEG (BAX 855) EU U.S. & Japan VONVENDI (BAX 111) EU U.S. OBIZUR: Acquired Hemophilia A U.S. & EU rADAMTS13 (BAX 930) FIX Gene Therapy (BAX 335) EHL rFVIII PSA (BAX 82
Slide 12: Advancing External Innovation Through Successful Partnerships & Acquisitions
Advancing External Innovation Through Successful Partnerships & Acquisitions Partnerships Acquisitions Chatham Therapeutics Baxalta Performance Update | Q1 2016 | Page 12
Slide 13: Baxalta: A Compelling & Unique Investment Opportunity
Baxalta: A Compelling & Unique Investment Opportunity • Established $6 billion global biopharmaceutical leader focused on orphan diseases • Well positioned in attractive and growing markets with differentiated therapies Leadership • Strong global channels and patient relationships and potential to b
Slide 14: Financial Summary
Financial Summary Baxalta Q1 2016 Performance Update
Slide 15: Balanced Performance Across The Portfolio
Balanced Performance Across The Portfolio Hematology* Immunology* Oncology Q1 2016 Q1 2016 Q1 2016 Strong ADVATE and FEIBA Strong market acceptance Completed ONCASPAR performance of HYQVIA acquisition Successful launch of Commenced ONCASPAR Enhanced supply position ADYNOVATE in U.S. launch across EU
Slide 16: Q1 2016 Adjusted Financial Results
Q1 2016 Adjusted Financial Results* Q1 2016 Key Performance Drivers Actual Results • Strong and balanced growth across business portfolio Sales ($ in Millions) $1,548 • Enhanced gross margin profile reflects: Growth** +14% - Historical seasonality - Positive mix benefits and modest price Gross Margi
Slide 17: Business Review
Business Review Baxalta Q1 2016 Performance Update
Slide 18: Hematology
Hematology Hematology Positioned For Growth • Strengthening our hematology leadership with broad portfolio of treatment options Strong global Strengthening presence and growth leadership and • Building personalized care through sustainability patient-centric innovation • Elevating access to treatmen
Slide 19: Hematology: Q1 2016 Results
Hematology: Q1 2016 Results Q1 2016 Sales % Growth | At Actual % Growth | At Constant $ In Millions U.S. Int. Total U.S. Int. Total U.S. Int. Total Hemophilia $346 $298 $644 +13% -11% +0% +13% -4% +4% Inhibitor Therapies $71 $128 $199 +13% +24% +20% +13% +32% +25% Hematology $417 $426 $843 +13% -3%
Slide 20: Hematology: Quarterly Sales Growth
Hematology: Quarterly Sales Growth Hemophilia Inhibitor Therapies % Sales Growth At Constant Currency % Sales Growth At Constant Currency Baxalta Performance Update | Q1 2016 | Page 20
Slide 21: Unique And Attractive Global FVIII Market
Unique And Attractive Global FVIII Market Distinct Market Characteristics 2014 Global FVIII Market • High brand loyalty and very low patient turnover despite eight competitors • Safety and efficacy are top considerations • Trusted safety profile requires years of real-world experience to establish •
Slide 22: ADYNOVATE: Blockbuster Potential
ADYNOVATE: Blockbuster Potential Positioned To Grow And Lead EHL • ADYNOVATE launched in U.S. during Q4 2015 - Single-digit price premium to ADVATE on an annual cost of therapy basis - 60%+ HTC penetration with positive patient/prescriber Key Attributes response to product profile • Strong IP Positi
Slide 23: FVIII Replacement Therapies Set High Bar For Hemophilia Treatments
FVIII Replacement Therapies Set High Bar For Hemophilia Treatments Non-Factor Approaches Need To Additional Benefits Of FVIII May Not Be Address Important Efficacy And Replicated By Non-Factor Approaches Safety Questions: Fully measurable via assays Effective for breakthrough bleeds, surgery, and bl
Slide 24: Immunology
Immunology Immunology Positioned For Growth • Building leadership in global markets characterized by robust demand • Capitalizing on a broad, differentiated Driving global Capitalizing on awareness and transformational IG portfolio demand differentiation • Improving supply with flexible, cost- effec
Slide 25: Immunology: Q1 2016 Results
Immunology: Q1 2016 Results* Q1 2016 Sales % Growth | At Actual % Growth | At Constant $ In Millions U.S. Int. Total U.S. Int. Total U.S. Int. Total Immunoglobulin $356 $97 $453 +9% +5% +8% +9% +16% +10% Therapies BioTherapeutics $65 $135 $200 +10% +15% +14% +10% +23% +19% Immunology $421 $232 $653
Slide 26: Immunology: Quarterly Sales Growth
Immunology: Quarterly Sales Growth Immunoglobulin Therapies Pro Forma BioTherapeutics* % Sales Growth At Constant Currency % Sales Growth At Constant Currency *2014 constant currency growth rates do not include pro forma adjustments Baxalta Performance Update | Q1 2016 | Page 26
Slide 27: Capitalizing On Transformational Differentiation With HYQVIA
Capitalizing On Transformational Differentiation With HYQVIA HYQVIA Source Of Patients Global PID Indication: ~8% CAGR* Internal Estimates % By Route Of Administration In 2020 Capturing SubQ Leadership Position With HYQVIA By 2020 *2015 – 2020 CAGR Baxalta Performance Update | Q1 2016 | Page 27
Slide 28: Flexible And Cost-Effective Capacity Supports Future Demand Growth
Flexible And Cost-Effective Capacity Supports Future Demand Growth Cost-Effective Expansion Baxalta Fractionation Capacity** Liters In Millions • Disciplined investment to support continued growth in demand 8%+ CAGR • Internal network combined with Sanquin CMO provides cost-effective and flexible ne
Slide 29: Oncology
Oncology Oncology Positioned For Growth • Capitalizing on an attractive and growing market • Focusing on orphan diseases and targeted Extracting value with FDA approval reflects populations with significant unmet need geographic and significance of unmet indication expansions medical need • Collabor
Slide 30: Exciting Oncology Growth Prospects
Exciting Oncology Growth Prospects • Integral component of many ALL • Statistically significant survival benefit treatment guidelines - 5-FU/LV of 6.1 months versus 4.2 months • 90% cure rate for children; 50% in young Value adults; 30% in adults - 5-FU/LV of 3.1 months versus 1.5 months Proposition
Slide 31: GAAP To Pro Forma Non-GAAP Reconciliations
GAAP To Pro Forma Non-GAAP Reconciliations
Slide 32: Notice To Investors
Notice To Investors Non-GAAP Financial Measures: The financial information included in these schedules includes financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP). Reconciliations of the GAAP to non-GAAP financial measures can be found on pa
Slide 33: Pro Forma Sales Reconciliation
Pro Forma Sales Reconciliation Q1 2016 Q1 2015 % Growth @ Actual Rates % Growth @ Constant Rates U.S. International Total U.S. International Total U.S. International Total U.S. International Total Hemophilia $346 $298 $644 $305 $336 $641 13% (11%) 0% 13% (4%) 4% Inhibitor Therapies 71 128 199 63 103
Slide 34: GAAP To Non-GAAP Reconciliation: Gross Margin
GAAP To Non-GAAP Reconciliation: Gross Margin $ in millions Q1 2016 Gross Margin $838 Gross Margin Percentage 54.1% Adjustments for special items 96 Adjusted Gross Margin $934 Adjusted Gross Margin Percentage 60.3% Baxalta Performance Update | Q1 2016 | Page 34
Slide 35: GAAP To Non-GAAP Reconciliation: Operating Income And EBITDA
GAAP To Non-GAAP Reconciliation: Operating Income And EBITDA $ in millions Q1 2016 Pre-tax Income $172 Pre-tax Income Margin 11.1% Adjustments for special items 231 Adjusted Pre-tax Income 403 Adjusted Pre-tax Income Margin 26.0% Remove: Net interest expense 23 Remove: Other income (1) Adjusted Oper
Slide 36: GAAP To Non-GAAP Reconciliation: Tax Rate And Diluted EPS
GAAP To Non-GAAP Reconciliation: Tax Rate And Diluted EPS $ in millions Q1 2016 Income tax expense $27 Tax rate 15.7% Adjustments for special items 50 Adjusted Income tax expense $77 Adjusted tax rate 19.1% Q1 2016 Diluted EPS $0.21 Adjustments for special items 0.26 Adjusted Diluted EPS $0.47 Baxal